Remdesivir Is Big Win for Gilead -- Boosted by Taxpayers Remdesivir Is Big Win for Gilead -- Boosted by Taxpayers

Its emergency-use approval by the FDA immediately drew a storm of criticism. The World Health Organization recommended against its use. Politicians railed at its $3,120 price tag.Kaiser Health News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news